Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.

“On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors,” said Caro Van Hove, Executive Chair of Sientra. “With Kevin O’Boyle retiring from the Board after nearly a decade of exceptional Board leadership and financial governance, Alex’s deep strategic and operational expertise across the life sciences industry is an excellent match and of great value to Sientra’s continued double-digit growth plan and commitment to a strong financial position.”

Mr. Casdin has deep experience as a healthcare operating executive, investor and advisor with more than twenty years of experience. Mr. Casdin is currently the Chief Operating Officer of Epirium Bio, a biotechnology company with a small molecule platform of therapies targeted to improve muscle function. Mr. Casdin also served as Epirium’s Chief Financial Officer prior to his current role. Before joining Epirium, Mr. Casdin was founder and Chief Executive & Chief Investment Officer (CEO-CIO) of Reneo Capital Management LP, a healthcare investment fund. In addition, he served in roles as Chief Financial Officer of Sophiris Bio, Inc; Vice President of Finance at Amylin Pharmaceuticals; and Portfolio Manager for Health Care at Pequot capital. He also led Casdin Advisors, LLC, a strategic advisory firm providing services in the life science industry.

Mr. Casdin has served on the Board of Directors of multiple successful healthcare companies, and helped steward those companies to successful IPOs and or acquisitions, including Ignyta, Inc. and Dusa Pharmaceuticals, Inc, which were acquired by Roche and Sun Pharmaceuticals, respectively. He currently serves as a Board member and Audit Chair of Erasca, Inc. In addition, Mr. Casdin is currently a Board member and Treasurer of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) and serves on the Advisory Board for the Hassenfeld Children’s Center at NYU Langone Medical Center.

“I am very pleased to be joining the Board of Sientra at this important time,” said Mr. Casdin. “The Company’s leadership in breast reconstruction, as demonstrated by its continued market share gains and its impressive disruptive new technologies, coupled with its commitment to disciplined cash management, creates an exciting opportunity to deliver meaningful shareholder value. I look forward to collaborating with the Board and senior management team to support Sientra in its mission to be the most innovative and trusted partner to plastic surgeons and patients.”

About Sientra

Headquartered in Irvine, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth-generation breast implants approved by the FDA for sale in the United States, its ground-breaking AlloX2® breast tissue expander with patented dual-port and integral drain technology, the Viality™ with AuraClens™ enhanced viability fat transfer system, the SimpliDerm® Human Acellular Dermal Matrix, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at

(*) Data on file

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Forward-looking statements may include information concerning the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, profitability, outlook, and overall business strategy, the Company’s ability and timing to successfully integrate new products into its existing operations, the clinical performance of the Company’s products, the reception of plastic surgeons to the Company’s products, and the Company’s ability to capture additional market share and customer accounts in the plastic surgery market. Such statements are subject to risks and uncertainties, including the positive reaction from plastic surgeons and their patients to the Company’s products, the ability to meet consumer demand, including any potential supply issues resulting from the COVID-19 pandemic or the war in Ukraine, the growth of the plastic surgery market and breast procedures, and the ability of the Company to execute on its commercial, marketing, research and development and regulatory plans. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Investor Relations Contact
Aman R. Patel, CFA

error: Content is protected !!